The ExteNET study demonstrated a significant reduction in the risk of disease recurrence when neratinib was initiated within 1 year of trastuzumab-based therapy in a population of patients with treated HER2+/HR+ BC (75). The gene discussed is ERBB2; the disease is breast cancer.